Why can’t US MSOs list on senior exchanges in the US?
Currently, the same holds true for institutional investors.
Once cannabis moved to Schedule III - you'll see a major shift in the US cannabis sector.
"Nasdaq COMP requirements prohibit companies with direct exposure to cannabis from listing on its exchanges because cannabis remains a Schedule I drug under federal law. Schedule I is the Drug Enforcement Administration’s most restrictive category."